Bank of America Securities Raises TIGERMED Target Price to HK$56, Reiterates "Buy" Rating

Stock News

Sep 01

Bank of America Securities issued a research report stating that TIGERMED's second quarter total revenue increased 7.8% quarter-over-quarter to RMB 1.686 billion, with total gross profit rising 8.2% quarter-over-quarter to RMB 508 million. The gross margin improved by 0.1 percentage point quarter-over-quarter to 30.1%, while the company recorded a net loss of RMB 129 million. The firm has lowered its revenue forecasts for TIGERMED for 2025-2027 by 10% respectively, while raising the target price from HK$40.6 to HK$56 and reaffirming its "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1147365870"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147365870\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147365870?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-01 15:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147365870","market":"us","top_or_hot":-1,"title":"Bank of America Securities Raises TIGERMED Target Price to HK$56, Reiterates \"Buy\" Rating","media":"Stock News","content":"<p>Bank of America Securities issued a research report stating that TIGERMED's second quarter total revenue increased 7.8% quarter-over-quarter to RMB 1.686 billion, with total gross profit rising 8.2% quarter-over-quarter to RMB 508 million. The gross margin improved by 0.1 percentage point quarter-over-quarter to 30.1%, while the company recorded a net loss of RMB 129 million. The firm has lowered its revenue forecasts for TIGERMED for 2025-2027 by 10% respectively, while raising the target price from HK$40.6 to HK$56 and reaffirming its \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bank of America Securities Raises TIGERMED Target Price to HK$56, Reiterates \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBank of America Securities Raises TIGERMED Target Price to HK$56, Reiterates \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-01 15:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bank of America Securities issued a research report stating that TIGERMED's second quarter total revenue increased 7.8% quarter-over-quarter to RMB 1.686 billion, with total gross profit rising 8.2% quarter-over-quarter to RMB 508 million. The gross margin improved by 0.1 percentage point quarter-over-quarter to 30.1%, while the company recorded a net loss of RMB 129 million. The firm has lowered its revenue forecasts for TIGERMED for 2025-2027 by 10% respectively, while raising the target price from HK$40.6 to HK$56 and reaffirming its \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1146622755.USD","symbol_name":"安本中国A股股票基金A Acc","start_time":0,"source_url":"","article_id":"1147365870","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147365870","pubTimestamp":1756711943,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Bank of America Securities issued a research report stating that TIGERMED's second quarter total revenue increased 7.8% quarter-over-quarter to RMB 1.686 billion, with total gross profit rising 8.2%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161027":"证券","300347":"泰格医药","LU1146622755.USD":"安本中国A股股票基金A Acc","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0216":"研究试验","BK0028":"国家队","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","03347":"泰格医药","BK0174":"增持","BK0077":"质押式回购"},"translate_title":"美银证券上调泰格医药目标价至56港元重申“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161027":1,"300347":1,"03347":1},"content_text":"Bank of America Securities issued a research report stating that TIGERMED's second quarter total revenue increased 7.8% quarter-over-quarter to RMB 1.686 billion, with total gross profit rising 8.2% quarter-over-quarter to RMB 508 million. The gross margin improved by 0.1 percentage point quarter-over-quarter to 30.1%, while the company recorded a net loss of RMB 129 million. The firm has lowered its revenue forecasts for TIGERMED for 2025-2027 by 10% respectively, while raising the target price from HK$40.6 to HK$56 and reaffirming its \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}